Lineage Cell Therapeutics (LCTX) Change in Acquisitions & Divestments: 2023-2025
Historic Change in Acquisitions & Divestments for Lineage Cell Therapeutics (LCTX) over the last 2 years, with Mar 2025 value amounting to $2.0 million.
- Lineage Cell Therapeutics' Change in Acquisitions & Divestments was N/A to $2.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $9.0 million, marking a year-over-year change of. This contributed to the annual value of $7.0 million for FY2024, which is 88.95% down from last year.
- Lineage Cell Therapeutics' Change in Acquisitions & Divestments amounted to $2.0 million in Q1 2025, which was down 33.33% from $3.0 million recorded in Q4 2024.
- Lineage Cell Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $24.3 million for Q2 2023, and its period low was $18,000 during Q2 2024.
- Moreover, its 3-year median value for Change in Acquisitions & Divestments was $4.9 million (2023), whereas its average is $9.0 million.
- Data for Lineage Cell Therapeutics' Change in Acquisitions & Divestments shows a maximum YoY crashed of 99.93% (in 2024) over the last 5 years.
- Over the past 3 years, Lineage Cell Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $9.8 million in 2023, then tumbled by 69.49% to $3.0 million in 2024, then reached $2.0 million in 2025.
- Its Change in Acquisitions & Divestments was $2.0 million in Q1 2025, compared to $3.0 million in Q4 2024 and $4.0 million in Q3 2024.